Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis.

<h4>Introduction</h4>2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Reports recommends that patients with clinically significant symptoms and exacerbations of chronic obstructive pulmonary disease (COPD) should escalate to triple therapy, a combined use of inhaled cor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yixuan Jiang, Hao Hu, Siu-Wai Leung
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/877c6ad7b0984407a30aea2b3ed51881
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:877c6ad7b0984407a30aea2b3ed51881
record_format	dspace
spelling	oai:doaj.org-article:877c6ad7b0984407a30aea2b3ed518812021-12-02T20:18:38ZComparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis.1932-620310.1371/journal.pone.0255545https://doaj.org/article/877c6ad7b0984407a30aea2b3ed518812021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0255545https://doaj.org/toc/1932-6203<h4>Introduction</h4>2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Reports recommends that patients with clinically significant symptoms and exacerbations of chronic obstructive pulmonary disease (COPD) should escalate to triple therapy, a combined use of inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA) and long-acting b2-agonists (LABA)(ICS/LAMA/LABA). Triple therapy in fixed-dose combinations (FDCs), i.e., combining ICS, LABA with LAMA and administrating by a single inhalation device, has appeared in recent years. This study aims to compare the efficacy of triple therapy in FDCs in treating patients with moderate to severe COPD.<h4>Methods and analyses</h4>Literature search will be conducted on PubMed, Embase and Web of science, according to pre-specified and corresponding search strategies, for relevant reports published since the inception dates of the databases. Randomised controlled trials (RCT) which compared the triple therapy in FDCs with other pharmacological therapies will be included. The Cochrane risk of bias assessment tool (RoB 2) will be used to assess the RCT quality. The outcomes will be analyzed as rate ratios and mean differences under a random-effects model in a frequentist network meta-analysis (NMA). Additional statistical analyses including subgroup analysis, sensitivity analysis, and publication bias analysis will be performed to assess the evidential heterogeneity and robustness. The strength of evidence from the NMA will be evaluated with the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) methods.<h4>Ethics and dissemination</h4>No ethics approval is required as this systematic review and network meta-analysis do not collect confidential personal data and do not carry out interventions in treating patients.<h4>Protocol registration number</h4>CRD42021240823.Yixuan JiangHao HuSiu-Wai LeungPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 8, p e0255545 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yixuan Jiang Hao Hu Siu-Wai Leung Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis.
description	<h4>Introduction</h4>2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Reports recommends that patients with clinically significant symptoms and exacerbations of chronic obstructive pulmonary disease (COPD) should escalate to triple therapy, a combined use of inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA) and long-acting b2-agonists (LABA)(ICS/LAMA/LABA). Triple therapy in fixed-dose combinations (FDCs), i.e., combining ICS, LABA with LAMA and administrating by a single inhalation device, has appeared in recent years. This study aims to compare the efficacy of triple therapy in FDCs in treating patients with moderate to severe COPD.<h4>Methods and analyses</h4>Literature search will be conducted on PubMed, Embase and Web of science, according to pre-specified and corresponding search strategies, for relevant reports published since the inception dates of the databases. Randomised controlled trials (RCT) which compared the triple therapy in FDCs with other pharmacological therapies will be included. The Cochrane risk of bias assessment tool (RoB 2) will be used to assess the RCT quality. The outcomes will be analyzed as rate ratios and mean differences under a random-effects model in a frequentist network meta-analysis (NMA). Additional statistical analyses including subgroup analysis, sensitivity analysis, and publication bias analysis will be performed to assess the evidential heterogeneity and robustness. The strength of evidence from the NMA will be evaluated with the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) methods.<h4>Ethics and dissemination</h4>No ethics approval is required as this systematic review and network meta-analysis do not collect confidential personal data and do not carry out interventions in treating patients.<h4>Protocol registration number</h4>CRD42021240823.
format	article
author	Yixuan Jiang Hao Hu Siu-Wai Leung
author_facet	Yixuan Jiang Hao Hu Siu-Wai Leung
author_sort	Yixuan Jiang
title	Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis.
title_short	Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis.
title_full	Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis.
title_fullStr	Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis.
title_full_unstemmed	Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis.
title_sort	comparative efficacy of single-inhaler triple therapies for copd: a protocol for systematic review and network meta-analysis.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/877c6ad7b0984407a30aea2b3ed51881
work_keys_str_mv	AT yixuanjiang comparativeefficacyofsingleinhalertripletherapiesforcopdaprotocolforsystematicreviewandnetworkmetaanalysis AT haohu comparativeefficacyofsingleinhalertripletherapiesforcopdaprotocolforsystematicreviewandnetworkmetaanalysis AT siuwaileung comparativeefficacyofsingleinhalertripletherapiesforcopdaprotocolforsystematicreviewandnetworkmetaanalysis
_version_	1718374294200778752

Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis.

Ejemplares similares